Bhagirath Palace runs on brand names. Medicinal marks are judged strictly — a drug name that looks or sounds close to another can be refused on safety grounds alone. Coin it clean, then file it.
Bhagirath Palace, off Chandni Chowk, is Asia's largest pharmaceutical market — a dense grid of distributors, C&F agents, PCD-franchise operators and own-label traders moving product across North India. Everything here trades on a brand name: the molecule may be generic, but the name on the strip is what the chemist reorders and the patient trusts. That name is a trademark asset, and in pharma it is governed by a stricter standard than almost any other category.
Two things distinguish pharma branding. First, medicinal marks are examined strictly for confusing similarity: because a mix-up between two drug names can cause a patient to take the wrong medicine, the Registrar and the courts apply a higher, safety-driven standard of scrutiny under Section 11 — marks that would pass in another field get refused here. Second, your trademark and your drug licence are completely separate approvals: a CDSCO/DCGI or state-FDA licence lets you make or sell the product, but confers no rights in the name. Pharma brands sit mainly in Class 5 (pharmaceuticals and medicinal preparations), with Class 35 for the distribution and trading function and Class 10 for medical devices and instruments. Delhi traders file from Delhi under the Dwarka registry, online. Begin with a rigorous search and file through Form TM-A.
Three filings cover most of the IP risk on day one. Each is a standalone service and each links to a deeper walkthrough.
Class 5 is the core: pharmaceuticals, medicinal and veterinary preparations, dietetic substances, disinfectants. If you also distribute, run a chain of stockists or operate a trading arm under a house name, Class 35 covers wholesale, distribution and retail services. And if your range extends into medical devices — surgical instruments, diagnostic apparatus, orthopaedic articles — those live in Class 10, not Class 5. Getting the specification right in Class 5 is delicate work; over-broad claims invite objections and near-conflicts. Confirm the categories on the class finder and cost the multi-class filing on the cost calculator first.
Distributors running large stockist and retailer networks share the brand-control challenges of the FMCG-distributor pattern, and healthcare-facing brands should also read trademark for Delhi healthcare chains.
Pharma naming is where most applications fail, and it fails on Section 11. In ordinary fields the test asks whether an average consumer would be confused; in medicine the standard is deliberately harsher, because the consequence of confusion is a patient taking the wrong drug. Registrars and courts therefore weigh phonetic similarity (does it sound alike when a chemist hears it across a counter?), visual similarity (does the strip look alike?) and the nature of the purchasers, and they resolve doubt in favour of caution. A name that is a hair away from an existing Class 5 mark will be refused even if a lay buyer might tell them apart.
So the coining discipline is: build a distinctive, invented name; avoid stems and prefixes already crowded in the molecule's space; and steer clear of names that merely describe the ailment or ingredient, which run into Section 9 absolute grounds. Screen it hard before you print a single carton — a thorough phonetic and visual search, backed by the free search tool, is not optional in this class. If the examination report still raises a similarity or descriptiveness citation, it becomes an objection-reply exercise, and a prior conflicting application can be met at the Journal stage with an opposition.
This is the second big misunderstanding on the Bhagirath Palace shop floor. A drug licence — whether a manufacturing licence, a wholesale/retail drug licence from the state FDA, or a CDSCO/DCGI approval — authorises you to deal in the product. It says nothing about who owns the brand name. You can hold a perfectly valid drug licence and still have no trademark rights in the name on the label; conversely, a trademark gives you no right to sell a drug without the requisite licence. They are parallel tracks and you need both. The regulatory-licence side is a compliance and licensing matter; the brand side is the trademark registration track — and the distinction between a brand and a mere entity name is the same one drawn in trademark vs company-name registration in Delhi.
Because these tracks are separate, ownership can drift — the licence in one entity, the brand used by another. Before a distribution buyout, a franchise rollout or an investment, an IP audit confirms the marks sit in the right entity, and any transfer is done cleanly by recorded assignment.
The PCD (Propaganda-cum-Distribution) franchise model is the engine of North Indian pharma trade: a brand owner appoints monopoly franchisees who market the range in a defined territory under the brand. That model only works if the brand is registered and the franchise relationship is documented. Register the mark first, then license it to your PCD partners through written agreements that fix territory, quality control and permitted use under Section 49 — the mechanics are on the trademark licensing page, and the underlying deal terms are a contracts exercise. Own-label traders commissioning production from third-party manufacturers face the same discipline: own the mark, control quality, license usage in writing.
A PCD brand licensed across a dozen territories without a registered trademark is a house built on sand: any franchisee, or any rival two lanes down in Bhagirath Palace, can adopt a near-identical name, and you have no clean statutory claim. In a first-to-file, strict-scrutiny class, the distributor who coins clean, screens hard and files first owns the name — and the licensing revenue that rides on it.
Sequence it tightly. Coin a distinctive name and run it through a strict phonetic and visual search against Class 5 before any packaging is printed. File in Class 5 (plus Class 35 and Class 10 where relevant) via TM-A — the government fee is ₹4,500 per class for MSMEs, startups and individuals on e-filing, and Udyam-registered traders should read the Udyam fee-concession guide. Keep the drug licences current on a separate track, put a Journal watch in place, and keep renewals on schedule. The wider regional playbook is in the complete 2026 Delhi guide, and MSME traders in adjacent Chandni Chowk lanes should read trademark filing for Delhi MSME wholesalers.
Coining a pharma brand or rolling out a PCD franchise? Screen it hard against Class 5 and file before the first carton is printed.
WhatsApp our team →Pharmaceuticals and medicinal preparations sit in Class 5. The distribution and trading function uses Class 35, and medical devices sit in Class 10, not Class 5. The class finder confirms the mix for your range.
Because a confusion between two drug names can cause a patient to take the wrong medicine. Under Section 11 the Registrar applies a higher, safety-driven standard of similarity, so a mark that would pass elsewhere can be refused in Class 5. A strict phonetic and visual search is essential before filing.
Yes. A drug licence lets you make or sell the product, but gives you no rights in the brand name — that is a separate trademark. Regulatory licensing is a compliance matter; the two run on parallel tracks and you need both.
Register the trademark first, then license it to your PCD partners through written agreements fixing territory and quality control under Section 49. Without registration you have no clean claim if a franchisee or rival adopts a near-identical name — the deal terms are a contracts exercise.